SUPPLEMENTARY PATIENTS AND METHODS
Patient Cohort
The enrollment period was lasted until 2006 A totals of 3807 HBsAg-positive patients, including 802 patients in a training cohort and 3005 patients in a validation cohort, who were older than 28 years and who underwent curative resection at the Liver Cancer Institute, Zhongshan Hospital, Fudan University, were consecutively enrolled between May 2001 and December 2006. After excluding patients with high HBV DNA loads, with evidence of hepatitis C virus (HCV) coinfection, without adequate serum for analysis, who relapsed within 1 month after surgery, and who were lost to follow-up, 298 patients in the training cohort and 1062 patients in the validation cohort were included in the analysis. A subgroup analysis was performed according to the HBsAg level: the patients were divided into those with low HBsAg levels (the HBsAgLow group; 109 patients in the training cohort and 422 patients in the validation cohort) and those with high HBsAg levels (the HBsAgHigh group;189 patients in the training cohort and 640 patients in the validation cohort).
Supplementary Figure Legend
Fig. S1. Kaplan-Meier analysis of patient survival according to HBsAg level in the training cohort. (A) Recurrence-free survival between the patients with an HBsAg level <10 IU/mL and an HBsAg level ≥10 IU/mL in the training cohort. (B) Recurrence-free survival between the patients with an HBsAg level <100 IU/mL and an HBsAg level ≥100 IU/mL in the training cohort.
Fig. S2. Kaplan-Meier analysis of patient survival in the training cohortaccording to ALT, GGT, and HBeAg levels. (A) Overall survival between the patients in the training cohort with an ALT level ≤75 U/L and an ALT level >75 U/L. (B) Recurrence-free survival between the patients in the training cohort with an ALT level ≤75 U/L and an ALT level>75 U/L. (C) Overall survival between the patients in the training cohort with a GGT level ≤54 U/L and a GGT level >54 U/L. (D) Recurrence-free survival between the patients in the training cohort with an ALT level ≤54 U/L and an ALT level >54 U/L. (E) Overall survival between the patients in the training cohort with negative HBeAg and positive HBeAg. (F) Recurrence-free survival between the patients in the training cohort with negative HBeAg and positive HBeAg.
Fig. S3. Kaplan-Meier analysis of patient survival in different subgroups of the training cohort according to HBsAg level.(A) EdmonsonIII–IV stage. (B) Vascular invasion. (C) AFP level >20 ng/mL. (D) GGT level >54 U/L. (E) BCLC stage 0+A.
Fig. S4. Receiving operating characteristic (ROC) curve analysis of HBsAg quantification in predicting OS (A) and recurrence (B).AUC, area under the curve.
Supplementary Table
Table S1. Clinicopathologic Features of the Training Cohort
Variable / Training Cohort (n=298) / Validation Cohort (n=1062)No. / % / No. / %
Sex / Female / 50 / 16.8 / 193 / 18.2
Male / 248 / 83.2 / 869 / 81.8
Age(year) / ≤50 / 123 / 41.3 / 412 / 38.8
>50 / 175 / 58.7 / 650 / 61.2
AFP / ≤20 / 104 / 34.9 / 398 / 37.5
>20 / 194 / 65.1 / 664 / 62.5
ALT(U/L) / ≤42 / 245 / 82.2 / 854 / 80.4
>42 / 53 / 17.8 / 208 / 19.6
GGT(U/L) / ≤54 / 156 / 52.3 / 532 / 50.1
>54 / 142 / 47.7 / 530 / 49.9
Liver cirrhosis / No / 45 / 15.1 / 195 / 18.4
Yes / 253 / 84.9 / 867 / 81.6
Tumor size(cm) / ≤5 / 192 / 64.4 / 703 / 66.2
>5 / 106 / 35.6 / 359 / 33.8
Tumor encapsulation / complete / 166 / 55.7 / 549 / 51.7
none / 132 / 44.3 / 513 / 48.3
Microvascular invasion / absence / 203 / 68.1 / 792 / 74.6
present / 95 / 31.9 / 270 / 25.4
Tumor differentiation / I+II / 219 / 73.5 / 759 / 71.5
III+IV / 79 / 26.5 / 303 / 28.5
TNM stage / I / 238 / 79.9 / 897 / 84.5
II+III / 60 / 20.1 / 165 / 15.5
HBeAg* / negative / 204 / 68.5 / 714 / 67.2
positive / 93 / 31.2 / 348 / 32.8
HBsAg level / < 1000 / 109 / 36.6 / 422 / 39.7
≥1000 / 189 / 65.4 / 640 / 60.3
Abbreviations: AFP, α-fetoprotein; ALT, alanine aminotransferase; GGT, γ-glutamyl transferase; TNM, tumor-node-metastasis; HBeAg, hepatitis B e antigen.
*One patient without HBeAg information was not calculated.